Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other hematologic neoplasm 2Myeloid 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Carboplatin 351pembrolizumab 327Pemetrexed 249Cisplatin 221Paclitaxel 149Nivolumab 139durvalumab 134Docetaxel 112osimertinib 111atezolizumab 107Specimen Handling 91Radiotherapy 89Drug Therapy 87Magnetic Resonance Spectroscopy 78Etoposide 78Radiosurgery 74Gemcitabine 72Ipilimumab 55130-nm albumin-bound paclitaxel 54Bevacizumab 53cemiplimab 47tislelizumab 46Blood Specimen Collection 43Cetuximab 35Taxes 34Injections 33Biopsy 33Standard of Care 32Platinum 32Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
iadademstat × Thoracic × 1 year × Clear all
NCT06287775 2026-05-22

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
45 enrolled
Thoracic

Lung Neoplasms

NCT05420636 2025-07-30

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Fox Chase Cancer Center

Phase 2 Terminated
20 enrolled
EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡